Thermo Fisher Scientific Advances Innovation for the Clinic at AACC 2017

SAN DIEGO, July 31, 2017 /PRNewswire/ -- AACC -- Thermo Fisher Scientific Inc. (TMO), the world leader in serving science, is showcasing its latest advancements in clinical and research-based solutions during the 2017 American Association of Clinical Chemistry (AACC) Annual Scientific Meeting & Clinical Lab Expo, being held July 31 – August 3 at the San Diego Convention Center. Among the products displayed within booth #4039 is a preview of the new Thermo Scientific Cascadion SM Clinical Analyzer, (in development and not available for sale), the world's first fully integrated laboratory analyzer that combines the ease of use of clinical analyzers with the selectivity and sensitivity of liquid chromatography-tandem mass spectrometry (LC-MS/MS) technology.*

More

"Advances in clinical diagnostics have the potential to improve healthcare by expanding the use of highly sensitive analytical tools that provide valuable patient information faster and more accurately," said Marc N. Casper, president and chief executive officer of Thermo Fisher Scientific. "Thermo Fisher is uniquely positioned to lead these innovations as a result of our commitment to adapt research-based technologies for use in clinical settings."

New and Expanded Diagnostic Tests

Thermo Fisher received FDA premarket approval for the first next-generation sequencing (NGS) companion diagnostic to help clinicians select targeted therapies for patients with non-small cell lung cancer (NSCLC). The Oncomine Dx Target Test is a qualitative in vitro diagnostic test that simultaneously screens tumor samples from biomarkers associated with three FDA-approved therapies for NSCLC. The test is part of a targeted sequencing workflow that includes the Ion PGM Dx System, and facilitates concurrent analysis of both DNA and RNA targets, enabling physicians to match patients to the right therapies in days instead of weeks.

Thermo Fisher also received 510(k) clearance from the FDA and CE-mark certification for the CEDIA* Buprenorphine II Assay, a new immunoassay to detect the controlled substance buprenorphine and three of its major metabolites. The ability to detect each of these metabolites is significant because it minimizes the potential for false-negative results and helps to screen patients receiving treatment for opiate addiction.

Lastly, the Thermo Scientific B.R.A.H.M.S. Procalcitonin (PCT) biomarker, used in determining treatment for sepsis, is now cleared for expanded use in the U.S. to aid clinicians in determining antibiotic therapy for patients with suspected or confirmed lower respiratory tract infections (LRTI). The B.R.A.H.M.S PCT biomarker can be used in an inpatient setting or an emergency department to help clinicians determine whether to discontinue antibiotic therapy for patients with LRTI or sepsis, without compromising patient safety.

Advancing Transplant Treatment Worldwide

To provide even greater value to our transplant diagnostics customers, Thermo Fisher recently announced that it acquired Linkage Biosciences, a provider of molecular diagnostic technologies for complex genetic testing. The business is highly complementary to the company's One Lambda tests, which determine the compatibility of donors and recipients pre- and post-transplant. This combination expands Thermo Fisher's commitment to improving transplant patients' quality of life through innovative high-quality products for the clinical and research segments of the transplant community.